Literature DB >> 30023384

Multi-drug therapy in breast cancer: are there any alternatives?

Partha Mitra1.   

Abstract

Entities:  

Year:  2018        PMID: 30023384      PMCID: PMC6036005          DOI: 10.21037/atm.2018.04.16

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  18 in total

1.  Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.

Authors:  Delphine Merino; James R Whittle; François Vaillant; Antonin Serrano; Jia-Nan Gong; Goknur Giner; Ana Leticia Maragno; Maïa Chanrion; Emilie Schneider; Bhupinder Pal; Xiang Li; Grant Dewson; Julius Gräsel; Kevin Liu; Najoua Lalaoui; David Segal; Marco J Herold; David C S Huang; Gordon K Smyth; Olivier Geneste; Guillaume Lessene; Jane E Visvader; Geoffrey J Lindeman
Journal:  Sci Transl Med       Date:  2017-08-02       Impact factor: 17.956

2.  Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Authors:  Shunqiang Li; Dong Shen; Jieya Shao; Robert Crowder; Wenbin Liu; Aleix Prat; Xiaping He; Shuying Liu; Jeremy Hoog; Charles Lu; Li Ding; Obi L Griffith; Christopher Miller; Dave Larson; Robert S Fulton; Michelle Harrison; Tom Mooney; Joshua F McMichael; Jingqin Luo; Yu Tao; Rodrigo Goncalves; Christopher Schlosberg; Jeffrey F Hiken; Laila Saied; Cesar Sanchez; Therese Giuntoli; Caroline Bumb; Crystal Cooper; Robert T Kitchens; Austin Lin; Chanpheng Phommaly; Sherri R Davies; Jin Zhang; Megha Shyam Kavuri; Donna McEachern; Yi Yu Dong; Cynthia Ma; Timothy Pluard; Michael Naughton; Ron Bose; Rama Suresh; Reida McDowell; Loren Michel; Rebecca Aft; William Gillanders; Katherine DeSchryver; Richard K Wilson; Shaomeng Wang; Gordon B Mills; Ana Gonzalez-Angulo; John R Edwards; Christopher Maher; Charles M Perou; Elaine R Mardis; Matthew J Ellis
Journal:  Cell Rep       Date:  2013-09-19       Impact factor: 9.423

Review 3.  HER2-positive breast cancer.

Authors:  Sibylle Loibl; Luca Gianni
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

4.  CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer.

Authors:  Sherene Loi; Sandra Pommey; Benjamin Haibe-Kains; Paul A Beavis; Phillip K Darcy; Mark J Smyth; John Stagg
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

5.  Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome.

Authors:  Michelle L Baglia; Qiuyin Cai; Ying Zheng; Jie Wu; Yinghao Su; Fei Ye; Ping-Ping Bao; Hui Cai; Zhiguo Zhao; Justin Balko; Wei Zheng; Wei Lu; Xiao-Ou Shu
Journal:  Breast Cancer Res Treat       Date:  2014-10-04       Impact factor: 4.872

6.  Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Authors:  Daniel P Silver; Andrea L Richardson; Aron C Eklund; Zhigang C Wang; Zoltan Szallasi; Qiyuan Li; Nicolai Juul; Chee-Onn Leong; Diana Calogrias; Ayodele Buraimoh; Aquila Fatima; Rebecca S Gelman; Paula D Ryan; Nadine M Tung; Arcangela De Nicolo; Shridar Ganesan; Alexander Miron; Christian Colin; Dennis C Sgroi; Leif W Ellisen; Eric P Winer; Judy E Garber
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

7.  Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.

Authors:  C M Goodwin; O W Rossanese; E T Olejniczak; S W Fesik
Journal:  Cell Death Differ       Date:  2015-06-05       Impact factor: 15.828

8.  MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.

Authors:  Adelaide I J Young; Andrew M K Law; Lesley Castillo; Sabrina Chong; Hayley D Cullen; Martin Koehler; Sebastian Herzog; Tilman Brummer; Erinna F Lee; Walter D Fairlie; Morghan C Lucas; David Herrmann; Amr Allam; Paul Timpson; D Neil Watkins; Ewan K A Millar; Sandra A O'Toole; David Gallego-Ortega; Christopher J Ormandy; Samantha R Oakes
Journal:  Breast Cancer Res       Date:  2016-12-08       Impact factor: 6.466

9.  CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.

Authors:  Partha Mitra; Ren-Ming Yang; James Sutton; Robert G Ramsay; Thomas J Gonda
Journal:  Oncotarget       Date:  2016-02-23

10.  MCL-1 is a prognostic indicator and drug target in breast cancer.

Authors:  Kirsteen J Campbell; Sandeep Dhayade; Nicola Ferrari; Andrew H Sims; Emma Johnson; Susan M Mason; Ashley Dickson; Kevin M Ryan; Gabriela Kalna; Joanne Edwards; Stephen W G Tait; Karen Blyth
Journal:  Cell Death Dis       Date:  2018-01-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.